-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The treatment of pediatric multiple sclerosis (POMS) is based on the use of disease-modifying therapies (DMTs) that have been tested in adults
Only fingolimod was tested in a randomized clinical trial (RCT) and showed that it is more effective in clinical and MRI results than interferon beta
manage
With this, Damiano Baroncini and others of the University of Bari Aldo Moro explored whether the course of POMS changes with changes in treatment and management standards
We explored whether the course of POMS changes with changes in treatment and management standards
A total of 3198 POMS patients were recruited (mean age at onset was 15.
The median survival time to reach EDSS scores of 4.
Over time, the cumulative risk of reaching disability milestones gradually decreased, both for EDSS scores of 4.
The significance of this study is that in POMS patients, the risk of persistent disability has been reduced by 50% to 70% in the most recent diagnosis, which may be due to improvements in treatment and management standards
In POMS patients, the risk of persistent disability has been reduced by 50% to 70% in the most recent diagnosis period.
JAMA
is here to leave a message